GeNeuro’s Causal Approach To MS Treatment Gathers Momentum
GeNeuro is making good progress on its mid-stage clinical compound that is tackling a potential cause of multiple sclerosis. An early collaboration with Servier puts the Swiss biotech on a good footing if an ongoing Phase IIb trial – due to report interim data at the end of next year – is successful.
You may also be interested in...
Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.
Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.